580 related articles for article (PubMed ID: 27655102)
1. B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases.
Uzzan M; Colombel JF; Cerutti A; Treton X; Mehandru S
Dig Dis Sci; 2016 Dec; 61(12):3407-3424. PubMed ID: 27655102
[TBL] [Abstract][Full Text] [Related]
2. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
Lenert A; Lenert P
Drug Des Devel Ther; 2015; 9():333-47. PubMed ID: 25609919
[TBL] [Abstract][Full Text] [Related]
3. Aging murine B cells have decreased class switch induced by anti-CD40 or BAFF.
Frasca D; Riley RL; Blomberg BB
Exp Gerontol; 2007 Mar; 42(3):192-203. PubMed ID: 17067770
[TBL] [Abstract][Full Text] [Related]
4. [Role of B-cell-activating-factor in immune regulation--review].
Du JF; Wang JX; Xu DG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Jun; 14(3):631-4. PubMed ID: 16800959
[TBL] [Abstract][Full Text] [Related]
5. BAFF, APRIL and human B cell disorders.
Tangye SG; Bryant VL; Cuss AK; Good KL
Semin Immunol; 2006 Oct; 18(5):305-17. PubMed ID: 16916610
[TBL] [Abstract][Full Text] [Related]
6. Fingolimod induces BAFF and expands circulating transitional B cells without activating memory B cells and plasma cells in multiple sclerosis.
Miyazaki Y; Niino M; Takahashi E; Suzuki M; Mizuno M; Hisahara S; Fukazawa T; Amino I; Nakano F; Nakamura M; Akimoto S; Minami N; Fujiki N; Doi S; Shimohama S; Terayama Y; Kikuchi S
Clin Immunol; 2018 Feb; 187():95-101. PubMed ID: 29079163
[TBL] [Abstract][Full Text] [Related]
7. CD40- and CD95-specific antibody single chain-Baff fusion proteins display BaffR-, TACI- and BCMA-restricted agonism.
Nelke J; Medler J; Weisenberger D; Beilhack A; Wajant H
MAbs; 2020; 12(1):1807721. PubMed ID: 32840410
[TBL] [Abstract][Full Text] [Related]
8. A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers.
Wong DP; Roy NK; Zhang K; Anukanth A; Asthana A; Shirkey-Son NJ; Dunmire S; Jones BJ; Lahr WS; Webber BR; Moriarity BS; Caimi P; Parameswaran R
Nat Commun; 2022 Jan; 13(1):217. PubMed ID: 35017485
[TBL] [Abstract][Full Text] [Related]
9. B cell activating factor (BAFF) and BAFF receptors: fakes and facts.
Ferraccioli G; Gremese E
Clin Exp Immunol; 2017 Dec; 190(3):291-292. PubMed ID: 28834574
[TBL] [Abstract][Full Text] [Related]
10. The role of the BAFF/APRIL system on T cell function.
Mackay F; Leung H
Semin Immunol; 2006 Oct; 18(5):284-9. PubMed ID: 16931039
[TBL] [Abstract][Full Text] [Related]
11. The role of APRIL - A proliferation inducing ligand - In autoimmune diseases and expectations from its targeting.
Baert L; Manfroi B; Casez O; Sturm N; Huard B
J Autoimmun; 2018 Dec; 95():179-190. PubMed ID: 30385081
[TBL] [Abstract][Full Text] [Related]
12. B cell phenotypes in patients with rheumatoid arthritis relapsing after rituximab: expression of B cell-activating factor-binding receptors on B cell subsets.
Becerra E; De La Torre I; Leandro MJ; Cambridge G
Clin Exp Immunol; 2017 Dec; 190(3):372-383. PubMed ID: 28800164
[TBL] [Abstract][Full Text] [Related]
13. A mouse model of systemic lupus erythematosus responds better to soluble TACI than to soluble BAFFR, correlating with depletion of plasma cells.
Haselmayer P; Vigolo M; Nys J; Schneider P; Hess H
Eur J Immunol; 2017 Jun; 47(6):1075-1085. PubMed ID: 28383107
[TBL] [Abstract][Full Text] [Related]
14. Targeting T and B lymphocytes in inflammatory bowel diseases: lessons from clinical trials.
Gerner RR; Moschen AR; Tilg H
Dig Dis; 2013; 31(3-4):328-35. PubMed ID: 24246983
[TBL] [Abstract][Full Text] [Related]
15. BAFF, APRIL and their receptors: structure, function and signaling.
Bossen C; Schneider P
Semin Immunol; 2006 Oct; 18(5):263-75. PubMed ID: 16914324
[TBL] [Abstract][Full Text] [Related]
16. [Modulating the survival and maturation system of B lymphocytes: Current and future new therapeutic strategies in systemic lupus erythematosus].
Valor L; López-Longo FJ
Med Clin (Barc); 2015 Sep; 145(5):206-10. PubMed ID: 25433780
[TBL] [Abstract][Full Text] [Related]
17. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production.
Lavie F; Miceli-Richard C; Ittah M; Sellam J; Gottenberg JE; Mariette X
Ann Rheum Dis; 2007 May; 66(5):700-3. PubMed ID: 17040963
[TBL] [Abstract][Full Text] [Related]
18. [Research advances on B-cell activating factor and its targeted agents in inflammatory bowel disease].
Li L; Liu HY; Wang LJ
Zhongguo Dang Dai Er Ke Za Zhi; 2024 Mar; 26(3):315-320. PubMed ID: 38557386
[TBL] [Abstract][Full Text] [Related]
19. B-cell-targeted therapy for systemic lupus erythematosus.
Sabahi R; Anolik JH
Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
[TBL] [Abstract][Full Text] [Related]
20. [Recombinant proteins or monoclonal antibodies: comparative properties and interest in systemic lupus erythematosus].
Terrier B; Mouthon L
Med Sci (Paris); 2013 Jan; 29(1):65-73. PubMed ID: 23351696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
